Abstract
Immunology offers an unprecedented opportunity for the science-driven development of therapeutics. The successes of antibodies to the immunomodulatory receptor CTLA-4 and blockade of the immunoinhibitory receptor PD-1 in cancer immunotherapy, from gene discovery to patient benefit, have created a paradigm for driving such endeavors.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Application of additively manufactured 3D scaffolds for bone cancer treatment: a review
Bio-Design and Manufacturing Open Access 07 March 2022
-
Tumour heterogeneity and evolutionary dynamics in colorectal cancer
Oncogenesis Open Access 16 July 2021
-
CTLA4 has a profound impact on the landscape of tumor-infiltrating lymphocytes with a high prognosis value in clear cell renal cell carcinoma (ccRCC)
Cancer Cell International Open Access 27 October 2020
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
References
Flexner, A. Bull. World Health Organ. 80, 594–602 (2002).
Brahmer, J.R. et al. J. Clin. Oncol. 28, 3167–3175 (2010).
Brahmer, J.R. et al. N. Engl. J. Med. 366, 2455–2465 (2012).
Hodi, F.S. et al. N. Engl. J. Med. 363, 711–723 (2010).
Topalian, S.L. et al. N. Engl. J. Med. 366, 2443–2454 (2012).
Brunet, J.F. et al. Nature 328, 267–270 (1987).
Linsley, P.S. et al. J. Exp. Med. 173, 721–730 (1991).
Linsley, P.S. et al. J. Exp. Med. 174, 561–569 (1991).
Linsley, P.S. et al. J. Exp. Med. 176, 1595–1604 (1992).
Krummel, M.F. & Allison, J.P. J. Exp. Med. 182, 459–465 (1995).
Walunas, T.L. et al. Immunity 1, 405–413 (1994).
Tivol, E.A. et al. Immunity 3, 541–547 (1995).
Waterhouse, P. et al. Science 270, 985–988 (1995).
Leach, D.R., Krummel, M.F. & Allison, J.P. Science 271, 1734–1736 (1996).
Sutmuller, R.P. et al. J. Exp. Med. 194, 823–832 (2001).
Hodi, F.S. et al. Proc. Natl. Acad. Sci. USA 100, 4712–4717 (2003).
Phan, G.Q. et al. Proc. Natl. Acad. Sci. USA 100, 8372–8377 (2003).
Robert, C. et al. N. Engl. J. Med. 364, 2517–2526 (2011).
Hoos, A. et al. J. Natl. Cancer Inst. 102, 1388–1397 (2010).
Ishida, Y., Agata, Y., Shibahara, K. & Honjo, T. EMBO J. 11, 3887–3895 (1992).
Yokosuka, T. et al. J. Exp. Med. 209, 1201–1217 (2012).
Nishimura, H., Nose, M., Hiai, H., Minato, N. & Honjo, T. Immunity 11, 141–151 (1999).
Nishimura, H. et al. Science 291, 319–322 (2001).
Sharpe, A.H., Wherry, E.J., Ahmed, R. & Freeman, G.J. Nat. Immunol. 8, 239–245 (2007).
Dong, H., Zhu, G., Tamada, K. & Chen, L. Nat. Med. 5, 1365–1369 (1999).
Tseng, S.Y. et al. J. Exp. Med. 193, 839–846 (2001).
Freeman, G.J. et al. J. Exp. Med. 192, 1027–1034 (2000).
Latchman, Y. et al. Nat. Immunol. 2, 261–268 (2001).
Barber, D.L. et al. Nature 439, 682–687 (2006).
Dong, H. et al. Nat. Med. 8, 793–800 (2002).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The author declares no competing financial interests.
Rights and permissions
About this article
Cite this article
Pardoll, D. Immunology beats cancer: a blueprint for successful translation. Nat Immunol 13, 1129–1132 (2012). https://doi.org/10.1038/ni.2392
Published:
Issue Date:
DOI: https://doi.org/10.1038/ni.2392
This article is cited by
-
Application of additively manufactured 3D scaffolds for bone cancer treatment: a review
Bio-Design and Manufacturing (2022)
-
Tumour heterogeneity and evolutionary dynamics in colorectal cancer
Oncogenesis (2021)
-
Anti-PD-1 antibody decreases tumour-infiltrating regulatory T cells
BMC Cancer (2020)
-
Fasting to enhance Cancer treatment in models: the next steps
Journal of Biomedical Science (2020)
-
Challenges in diagnosis and management of neutropenia upon exposure to immune-checkpoint inhibitors: meta-analysis of a rare immune-related adverse side effect
BMC Cancer (2020)